scispace - formally typeset
D

Daniel Keszthelyi

Researcher at Maastricht University

Publications -  146
Citations -  3806

Daniel Keszthelyi is an academic researcher from Maastricht University. The author has contributed to research in topics: Irritable bowel syndrome & Medicine. The author has an hindex of 30, co-authored 115 publications receiving 2380 citations. Previous affiliations of Daniel Keszthelyi include King's College London & Maastricht University Medical Centre.

Papers
More filters
Journal ArticleDOI

Large-scale association analyses identify host factors influencing human gut microbiome composition

Alexander Kurilshikov, +109 more
- 18 Jan 2021 - 
TL;DR: In this article, the MiBioGen consortium curated and analyzed genome-wide genotypes and 16S fecal microbiome data from 18,340 individuals (24 cohorts) and found high variability across cohorts: only 9 of 410 genera were detected in more than 95% of samples.
Journal ArticleDOI

Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function

TL;DR: This review analyses the current knowledge of the interrelationship between tryptophan metabolic pathways and summarizes the existing scientific evidence regarding the role of tryptophile metabolites in intestinal function and in the pathogenesis of gastrointestinal diseases.
Posted ContentDOI

Large-scale association analyses identify host factors influencing human gut microbiome composition

Alexander Kurilshikov, +111 more
- 16 Dec 2020 - 
TL;DR: A phenome-wide association study and Mendelian randomization identified enrichment of microbiome trait loci in the metabolic, nutrition and environment domains and suggested the microbiome has causal effects in ulcerative colitis and rheumatoid arthritis.
Journal ArticleDOI

Leaky gut and diabetes mellitus: what is the link?

TL;DR: This review analyses recent advances in the mechanistic understanding of the role of the intestinal epithelial barrier function in the development of type 1 and type 2 diabetes to assume that reinforcing the intestinal barrier can offer and open new therapeutic horizons in the treatment of types 1 and 2 diabetes.